Accessibility Menu
Cannara Biotech logo

Cannara Biotech(TSXV) LOVE

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-35%
5 Year+17%
1 Year+12%
1 Month+7%
N/A
Cannara Biotech last closing stock price
MetricPriceDate
Last closeCAD 1.992026-09-02
Cannara Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%CAD 1.992026-08-26
1 month+6.99%CAD 1.862026-07-31
3 month+19.16%CAD 1.672026-06-04
Year to date+14.37%CAD 1.742025-12-31
1 year+11.8%CAD 1.782025-09-02
3 year+99%CAD 1.002023-09-01
5 year+17.06%CAD 1.702021-09-03
Since inception-34.75%CAD 3.052019-01-14

Cannara Biotech Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$113.26M

Net Income (TTM)

CA$10.16M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Apr 27, 2026

LOVE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cannara Biotech

Cannara Biotech Inc. specializes in the indoor cultivation, processing, and distribution of cannabis and related products across Canada. Established in 2017, the company operates a dual business model that includes cannabis operations and real estate activities, with a diverse product portfolio marketed under brand names such as TRIBAL, nugz, and ORCHID CBD.

Products and Services
  • Indoor cultivation of high-quality cannabis
  • Processing and distribution of cannabis products
  • Real estate activities related to cannabis operations
Growth Outlook
  • Revenue increased to CAD 31.83 million in Q3 2026
  • Net income reached CAD 4.84 million in the latest quarter
  • Strong gross profit margin of 21.58% indicates operational efficiency
Financial Highlights
  • Trailing twelve months (TTM) revenue of CAD 118.5 million
  • Current ratio of 2.99 suggests strong liquidity position
  • Net profit margin of 9.22% reflects profitability potential
Cannara Biotech Inc. has positioned itself as a key player in the Canadian cannabis market, leveraging its indoor cultivation capabilities and diverse product offerings. The company's recent financial performance indicates a positive trajectory, with significant revenue growth and a solid net income in the latest quarter. The strong gross profit margin further underscores the operational efficiency of the business model. With a current ratio of 2.99, Cannara Biotech demonstrates a robust liquidity position, which is essential for sustaining growth and navigating market challenges. Overall, the company appears well-equipped to capitalize on the expanding cannabis market in Canada.
AI Generated • Aug 30, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

452

CEO

Zohar Krivorot

Website

www.cannara.ca

Headquarters

Saint-Laurent, QC H4N 3M9, CA

LOVE Financials

Key Financial Metrics (TTM)

Gross Margin

26.30%

Operating Margin

0.10%

Net Income Margin

9.22%

Return on Equity

9.45%

Return on Capital

15.44%

Return on Assets

5.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

CA$43.18M

Operating Income

CA$13.38M

EBITDA

CA$24.34M

Operating Cash Flow

CA$27.11M

Capital Expenditure

-CA$11.53M

Free Cash Flow

CA$15.58M

Cash & ST Invst.

CA$21.90M

Total Debt

CA$34.22M

Cannara Biotech Performance Analysis

Cannara Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-08-31CAD 35,841,386N/A
20232023-08-31CAD 57,260,19359.8%
20242024-08-31CAD 81,747,55142.8%
20252025-08-31CAD 107,202,53531.1%
Cannara Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-312.8%
Q42025-08-314.8%
Q12025-11-305.2%
Q22026-02-28-9.7%
Cannara Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-08-31CAD 0.03N/A
20232023-08-31CAD 0.08196.9%
20242024-08-31CAD 0.07-9.5%
20252025-08-31CAD 0.14101.1%
Cannara Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-05-3124.5%
Q42025-08-31-19.0%
Q12025-11-30-70.2%
Q22026-02-2885.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$27.18M

+2.2%

Gross Profit

CA$11.65M

-2.6%

Gross Margin

42.86%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

461

N/A

Net Income

CA$1.66M

-49.8%

EBITDA

CA$4.63M

-36.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$21.90M

+333.3%

Total Debt

CA$34.22M

-30.0%

Accounts Receivable

CA$12.47M

-19.9%

Inventory

CA$54.15M

+19.2%

Long Term Debt

CA$25.22M

-26.0%

Short Term Debt

CA$9.00M

-39.1%

Return on Assets

5.58%

N/A

Return on Invested Capital

0.07%

N/A

Free Cash Flow

-CA$286.30K

+94.1%

Operating Cash Flow

CA$2.95M

+187.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HLS.TOHLS Therapeutics Inc.
CA$3.60-0.28%
RX.VBioSyent Inc.
CA$15.88-0.75%
CRDL.TOCardiol Therapeutics Inc.
CA$2.98-1.00%
XLY.TOAuxly Cannabis Group Inc.
CA$3.17+1.28%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.77-0.01%
HPEHewlett Packard Enterprise
$54.44+0.05%
FFord Motor Company
$14.41+0.02%
SNAPSnap
$5.70+0.02%

Questions About LOVE

What is the current price of Cannara Biotech?

Cannara Biotech is trading at N/A per share.

What is the 52-week range for Cannara Biotech?

Over the past 52 weeks, Cannara Biotech has traded between N/A and N/A.

How much debt does Cannara Biotech have?

As of the most recent reporting period, Cannara Biotech reported total debt of CA$37.00M.

How much cash does Cannara Biotech have on hand?

Cannara Biotech reported CA$21.81M in cash and cash equivalents in its most recent financial results.

What is Cannara Biotech’s dividend yield?

Cannara Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services